Novan Inc
F:6LUA
6LUA's latest stock split occurred on May 26, 2021
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, 6LUA traded at 7 per share. Afterward, the share price was about 7.
The adjusted shares began trading on May 26, 2021. This was the only stock split in 6LUA's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Feb 11, 2026
|
G
|
Great Republic Mining Corp
CNSX:GRM
|
1-for-10
/10
|
0.01 0.01 CAD | N/A |
|
Feb 11, 2026
|
|
Floridienne SA
F:OI9
|
10-for-1
x10
|
615 61.5 EUR | 63 63 EUR |
|
Feb 11, 2026
|
K
|
Kmc Properties ASA
OSE:KMCP
|
1-for-6
/6
|
5.717 34.302 NOK | 30.515 30.515 NOK |
|
Feb 11, 2026
|
|
Floridienne SA
XBRU:FLOB
|
10-for-1
x10
|
630 63 EUR | 65 65 EUR |
|
Feb 10, 2026
|
|
Southern Copper Corp
F:PCU
|
1-for-1
x1
|
175.45 173.1308 EUR | 167.5 167.5 EUR |
OI9
PCU
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
